Study of optical clocks based on ultracold ^171Yb atoms

The optical atomic clocks have the potential to transform global timekeeping,relying on the state-of-the-art accuracy and stability,and greatly improve the measurement precision for a wide range of scientific and technological applications.Herein we report on the development of the optical clock based on 171Yb atoms confined in an optical lattice.A minimum width of 1.92-Hz Rabi spectra has been obtained with a new 578-nm clock interrogation laser.The in-loop fractional instability of the 171Yb clock reaches 9.1×10-18 after an averaging over a time of 2.0×104 s.By synchronous comparison between two clocks,we demonstrate that our 171Yb optical lattice clock achieves a fractional instability of 4.60×10-16/√τ.

Low-dose immune tolerance induction for severe hemophilia A inhibitor patients:Immunosuppressants are generally not necessary for inhibitor-titer below 200 BU/mL

Importance:It remained unclear that the efficacy comparison between low-dose immune tolerance induction(LD-ITI)incorporating immunosuppressants(IS)when severe hemophilia A(SHA)patients had inhibitor-titer≥200 Bethesda Units(BU)/mL(LD-ITI-IS^(200) regimen)and LD-ITI combining with IS when SHA patients had inhibitor-titer≥40 BU/mL(LD-ITI-IS^(40) regimen).Objective:To compare the efficacy of the LD-ITI-IS^(200) regimen with that of the LD-ITI-IS^(40) regimen for SHA patients with high-titer inhibitors.Methods:A prospective cohort study on patients receiving LD-ITI-IS^(200) compared to those receiving LD-ITI-IS^(40) from January 2021 to December 2023.Both received LD-ITI[FVIII 50 IU/kg every other day].IS(rituximab+prednisone)was added when peak inhibitor tier≥200 BU/mL in the LD-ITI-IS^(200) regimen and≥40 BU/mL in the LD-ITI-IS^(40) regimen.Success is defined as a negative inhibitor plus FVIII recovery≥66%of the expected.Results:We enrolled 30 patients on LD-ITI-IS^(200) and 64 patients on LD-ITI-IS^(40),with similar baseline clinical characteristics.A lower IS-use rate was discovered in the LD-ITI-IS^(200) regimen compared to the LD-ITI-IS^(40) regimen(30.0%vs.62.5%).The two regimens(LD-ITI-IS^(200) vs.LD-ITI-IS^(40))had similar success rate(70.0%vs.79.7%),median time to success(9.4 vs.10.6 months),and annualized bleeding rate during ITI(3.7 vs.2.8).The cost to success was lower for LD-ITI-IS^(200) than for LD-ITI-IS^(40)(2107 vs.3256 US Dollar/kg).Among patients with peak inhibitor-titer 40-199 BU/mL,10 non-IS-using(on LD-ITI-IS^(200) regimen)and 28 IS-using(on LD-ITI-IS^(40) regimen)had similar success rates(70.0%vs.78.6%)and time to success(9.0 vs.8.8 months).Interpretation:In LD-ITI,IS are not necessary for inhibitor titer<200 BU/mL.

Apple SINA11-JAZ2 module is involved in jasmonate signaling response

Jasmonic acid(JA)is an important phytolipid hormone involved in regulating many processes of plant growth and development,and plays a key role in plant resistance to biotic and abiotic stresses.Since the first discovery of methyl jasmonate(MeJA)from jasminum in 1962,the JA signaling pathway have been dissected.